MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-Cell lymphoma

Ulrik Ralfkiaer, Lise Lindal, Thomas Litman, Lise Mette Gjerdrum, Charlotte Busch Ahler, Robert Gniadecki, Troels Marstrand, Simon Fredholm, Lars Iversen, Mariusz A. Wasik, Charlotte M. Bonefeld, Carsten Geisler, Thorbjorn Krejsgaard, Christian Glue, Mads Almose Ropke, Anders Woetmann, Lone Skov, Kirsten Gronbæk, Niels Odum*

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review


    Mycosis fungoides (MF) is the most common variant of cutaneous T-cell lymphoma (CTCL). MF is characterized by chronic inflammation dominated by cluster of differentiation 4-positive (CD4+) T-cells and T helper 2 cytokines, and as the malignant T-cell clone is initially elusive, early diagnosis is often impossible. MF usually takes an indolent course, but for unknown reasons may turn into an aggressive disease with a poor prognosis. Herein, we used a global quantitative real-time polymerase chain reaction platform to study microRNA (miR) expression in patients with early MF (n=13), more advanced CTCL (n=42), and atopic dermatitis (AD, n=20). Thirty-eight miRs were differentially expressed (≥2-fold) in early MF vs. AD and 36 in early MF vs. more advanced disease. miRs that distinguish early MF from AD included both up-regulated (miR-155, miR-146a, 146b-5p, miR-342-3p, let-7i∗) and downregulated (miR-203, miR-205) miRs previously implicated in advanced CTCL. When comparing early MF to more advanced CTCL, additional miRs were significantly upregulated including miRs which are part of the oncogenic miR-17/92, 106b/25 and 106a/363 clusters. In 16 patients for whom detailed follow-up data were available, 72 miRs were found differentially expressed between patients with progressive vs. those with non-progressive disease, again including miRs with a known relevance for lymphomagenesis, e.g. miR-155, miR-21, let-7i, miR-16, miR-142-3p, miR-146b-5p, miR-92a, miR-93 and miR-106a. In conclusion, we showed that early MF and AD display very different miR profiles despite their clinical, histological, and immunological similarities. During progression, an additional set of miRs becomes deregulated, suggesting their role in disease progression. These data suggest that miR profiling in CTCL may be a key to improving both diagnosis and risk prediction.

    Sider (fra-til)7207-7217
    Antal sider11
    TidsskriftAnticancer Research
    Udgave nummer12
    StatusUdgivet - 1 dec. 2014


    Udforsk hvilke forskningsemner 'MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-Cell lymphoma' indeholder.